Multiwavelength Observations of one Galaxy in Marano Field

We report the multiwavelength observations of one intermediate redshift (z=0.3884) galaxy in the Marano Field. These data include ISOCAM middle infrared, VLT/FORS2 spectroscopic and photometric data, associated with the ATCA 1.4 GHz radio and ROSAT PSPC X-ray observations from literature. The Spectral Energy Distribution obtained by VLT spectroscopy exhibits its early-type galaxy property, while, in the same time, it has obvious [OIII]5007 emission line. The diagnostic diagram from the optical emission line ratios shows its Seyfert galaxy property. Its infrared-radio relation follows the correlation of sources detected at 15 \mu and radio. It has a high X-ray luminosity of 1.26*10^{43} ergs/s, which is much higher than the general elliptical galaxies s with the similar B band luminosity, and is about 2 orders of magnitude higher than the derived value from the star forming tracer, the FIR luminosity. This means that the X-ray sources of this galaxy are not stellar components, but the AGN is the dominant component.Comment: 6 pages, 1 PS figure and 4 tables. Publication in ChJAA, Suppl., the Special Issue for The Fifth Microquasar Workshop 2004: http://chjaa.bao.ac.cn/, 2005, Vol.5, 335-34

Star formation rates of distant luminous infrared galaxies derived from Halpha and IR luminosities

We present a study of the star formation rate (SFR) for a sample of 16 distant galaxies detected by ISOCAM at 15um in the CFRS0300+00 and CFRS1400+52 fields. Their high quality and intermediate resolution VLT/FORS spectra have allowed a proper correction of the Balmer emission lines from the underlying absorption. Extinction estimates using the Hbeta/Hgamma and the Halpha/Hbeta Balmer decrement are in excellent agreement, providing a robust measurement of the instantaneous SFR based on the extinction-corrected Halpha luminosity. Star formation has also been estimated exploiting the correlations between IR luminosity and those at MIR and radio wavelengths. Our study shows that the relationship between the two SFR estimates follow two distinct regimes: (1) for galaxies with SFRIR below ~ 100Msolar/yr, the SFR deduced from Halpha measurements is a good approximation of the global SFR and (2) for galaxies near of ULIRGs regime, corrected Halpha SFR understimated the SFR by a factor of 1.5 to 2. Our analyses suggest that heavily extincted regions completely hidden in optical bands (such as those found in Arp 220) contribute to less than 20% of the global budget of star formation history up to z=1.Comment: (1) GEPI, Obs. Meudon, France ;(2) CEA-Saclay, France ;(3) ESO, Gemany ;(4) IAC, Spain. To appear in A&

Infrared microspectroscopy to elucidate the underlying biomolecular mechanisms of FLASH radiotherapy.

FLASH-radiotherapy (FLASH-RT) is an emerging modality that uses ultra-high dose rates of radiation to enable curative doses to the tumor while preserving normal tissue. The biological studies showed the potential of FLASH-RT to revolutionize radiotherapy cancer treatments. However, the complex biological basis of FLASH-RT is not fully known yet. Within this context, our aim is to get deeper insights into the biomolecular mechanisms underlying FLASH-RT through Fourier Transform Infrared Microspectroscopy (FTIRM). C57Bl/6J female mice were whole brain irradiated at 10 Gy with the eRT6-Oriatron system. 10 Gy FLASH-RT was delivered in 1 pulse of 1.8μs and conventional irradiations at 0.1 Gy/s. Brains were sampled and prepared for analysis 24 h post-RT. FTIRM was performed at the MIRAS beamline of ALBA Synchrotron. Infrared raster scanning maps of the whole mice brain sections were collected for each sample condition. Hyperspectral imaging and Principal Component Analysis (PCA) were performed in several regions of the brain. PCA results evidenced a clear separation between conventional and FLASH irradiations in the 1800-950 cm <sup>-1</sup> region, with a significant overlap between FLASH and Control groups. An analysis of the loading plots revealed that most of the variance accounting for the separation between groups was associated to modifications in the protein backbone (Amide I). This protein degradation and/or conformational rearrangement was concomitant with nucleic acid fragmentation/condensation. Cluster separation between FLASH and conventional groups was also present in the 3000-2800 cm <sup>-1</sup> region, being correlated with changes in the methylene and methyl group concentrations and in the lipid chain length. Specific vibrational features were detected as a function of the brain region. This work provided new insights into the biomolecular effects involved in FLASH-RT through FTIRM. Our results showed that beyond nucleic acid investigations, one should take into account other dose-rate responsive molecules such as proteins, as they might be key to understand FLASH effect

Management of the thrombotic risk associated with COVID-19:guidance for the hemostasis laboratory

Coronavirus disease 2019 (COVID-19) is associated with extreme inflammatory response, disordered hemostasis and high thrombotic risk. A high incidence of thromboembolic events has been reported despite thromboprophylaxis, raising the question of a more effective anticoagulation. First-line hemostasis tests such as activated partial thromboplastin time, prothrombin time, fibrinogen and D-dimers are proposed for assessing thrombotic risk and monitoring hemostasis, but are vulnerable to many drawbacks affecting their reliability and clinical relevance. Specialized hemostasis-related tests (soluble fibrin complexes, tests assessing fibrinolytic capacity, viscoelastic tests, thrombin generation) may have an interest to assess the thrombotic risk associated with COVID-19. Another challenge for the hemostasis laboratory is the monitoring of heparin treatment, especially unfractionated heparin in the setting of an extreme inflammatory response. This review aimed at evaluating the role of hemostasis tests in the management of COVID-19 and discussing their main limitations

Misleading results from low-resolution spectroscopy: from galaxy interstellar medium chemistry to cosmic star formation density

Low resolution spectroscopy (R=150) from the Canada-France-Redshift Survey (CFRS) had revealed intriguing properties for low redshift galaxies (z<=0.3): nearly half of their spectra show prominent H\alpha emission line, but no H\beta emission line and barely detected [O II]3727 and [O III]5007 lines. We call these objects "CFRS H\alpha-single" galaxies and have re-observed a subsample of them at higher spectral resolution, associated with a subsample of more normal emission line galaxies. Good S/N spectroscopy at the VLT and the CFHT, with moderate spectral resolution (R>600), reveals that the "CFRS H\alpha-single" galaxies and most of the star forming spirals have high extinctions (A_V>2), high stellar masses and over-solar oxygen abundances. The present study shows that it is hard to derive the detailed properties of galaxies (gas chemical abundances, interstellar extinction, stellar population, star formation rates and history) using spectra with resolution below 600. One major drawback is indeed that the underlying Balmer absorption cannot be estimated properly, which could cause the SFRs be either underestimated or overestimated by factors reaching 10 (average 3.1) for the sample galaxies. These effects are prominent for a large fraction of evolved massive galaxies especially those experiencing successive bursts (A and F stars dominating their absorption spectra). Further estimates of the cosmic star formation density at all redshifts mandatorily requires moderate resolution spectroscopy to avoid severe biases.Comment: 14 pages, 12 PS figures, Accepted for publication in A&

A rapid high-performance semi-automated tool to measure total kidney volume from MRI in autosomal dominant polycystic kidney disease.

OBJECTIVES: To develop a high-performance, rapid semi-automated method (Sheffield TKV Tool) for measuring total kidney volume (TKV) from magnetic resonance images (MRI) in patients with autosomal dominant polycystic kidney disease (ADPKD). METHODS: TKV was initially measured in 61 patients with ADPKD using the Sheffield TKV Tool and its performance compared to manual segmentation and other published methods (ellipsoidal, mid-slice, MIROS). It was then validated using an external dataset of MRI scans from 65 patients with ADPKD. RESULTS: Sixty-one patients (mean age 45 ± 14 years, baseline eGFR 76 ± 32 ml/min/1.73 m2) with ADPKD had a wide range of TKV (258-3680 ml) measured manually. The Sheffield TKV Tool was highly accurate (mean volume error 0.5 ± 5.3% for right kidney, - 0.7 ± 5.5% for left kidney), reproducible (intra-operator variability - 0.2 ± 1.3%; inter-operator variability 1.1 ± 2.9%) and outperformed published methods. It took less than 6 min to execute and performed consistently with high accuracy in an external MRI dataset of T2-weighted sequences with TKV acquired using three different scanners and measured using a different segmentation methodology (mean volume error was 3.45 ± 3.96%, n = 65). CONCLUSIONS: The Sheffield TKV Tool is operator friendly, requiring minimal user interaction to rapidly, accurately and reproducibly measure TKV in this, the largest reported unselected European patient cohort with ADPKD. It is more accurate than estimating equations and its accuracy is maintained at larger kidney volumes than previously reported with other semi-automated methods. It is free to use, can run as an independent executable and will accelerate the application of TKV as a prognostic biomarker for ADPKD into clinical practice. KEY POINTS: • This new semi-automated method (Sheffield TKV Tool) to measure total kidney volume (TKV) will facilitate the routine clinical assessment of patients with ADPKD. • Measuring TKV manually is time consuming and laborious. • TKV is a prognostic indicator in ADPKD and the only imaging biomarker approved by the FDA and EMA

Expression and methylation status of tissue factor pathway inhibitor-2 gene in non-small-cell lung cancer

Tissue factor pathway inhibitor-2 (TFPI-2) is a Kunitz-type serine proteinase inhibitor that inhibits plasmin-dependent activation of several metalloproteinases. Downregulation of TFPI-2 could thus enhance the invasive potential of neoplastic cells in several cancers, including lung cancer. In this study, TFPI-2 mRNA was measured using a real-time PCR method in tumours of 59 patients with non-small-cell lung cancer (NSCLC). Tumour TFPI-2 mRNA levels appeared well correlated with protein expression evaluated by immunohistochemistry and were 4–120 times lower compared to those of nonaffected lung tissue in 22 cases (37%). Hypermethylation of the TFPI-2 gene promoter was demonstrated by restriction enzyme-polymerase chain reaction in 12 of 40 cases of NSCLC (30%), including nine of 17 for whom tumour TFPI-2 gene expression was lower than in noncancerous tissue. In contrast, this epigenetic modification was shown in only three of 23 tumours in which no decrease in TFPI-2 synthesis was found (P=0.016). Decreased TFPI-2 gene expression and hypermethylation were more frequently associated with stages III or IV NSCLC (eight out of 10, P=0.02) and the TFPI-2 gene promoter was more frequently hypermethylated in patients with lymph node metastases (eight out of 16, P=0.02). These results suggest that silencing of the TFPI-2 gene by hypermethylation might contribute to tumour progression in NSCLC

Simple Shared Motifs (SSM) in conserved region of promoters: a new approach to identify co-regulation patterns

<p>Abstract</p> <p>Background</p> <p>Regulation of gene expression plays a pivotal role in cellular functions. However, understanding the dynamics of transcription remains a challenging task. A host of computational approaches have been developed to identify regulatory motifs, mainly based on the recognition of DNA sequences for transcription factor binding sites. Recent integration of additional data from genomic analyses or phylogenetic footprinting has significantly improved these methods.</p> <p>Results</p> <p>Here, we propose a different approach based on the compilation of Simple Shared Motifs (SSM), groups of sequences defined by their length and similarity and present in conserved sequences of gene promoters. We developed an original algorithm to search and count SSM in pairs of genes. An exceptional number of SSM is considered as a common regulatory pattern. The SSM approach is applied to a sample set of genes and validated using functional gene-set enrichment analyses. We demonstrate that the SSM approach selects genes that are over-represented in specific biological categories (Ontology and Pathways) and are enriched in co-expressed genes. Finally we show that genes co-expressed in the same tissue or involved in the same biological pathway have increased SSM values.</p> <p>Conclusions</p> <p>Using unbiased clustering of genes, Simple Shared Motifs analysis constitutes an original contribution to provide a clearer definition of expression networks.</p

The European Hematology Association Roadmap for European Hematology Research: a consensus document

The European Hematology Association (EHA) Roadmap for European Hematology Research highlights major achievements in diagnosis and treatment of blood disorders and identifies the greatest unmet clinical and scientific needs in those areas to enable better funded, more focused European hematology research. Initiated by the EHA, around 300 experts contributed to the consensus document, which will help European policy makers, research funders, research organizations, researchers, and patient groups make better informed decisions on hematology research. It also aims to raise public awareness of the burden of blood disorders on European society, which purely in economic terms is estimated at €23 billion per year, a level of cost that is not matched in current European hematology research funding. In recent decades, hematology research has improved our fundamental understanding of the biology of blood disorders, and has improved diagnostics and treatments, sometimes in revolutionary ways. This progress highlights the potential of focused basic research programs such as this EHA Roadmap. The EHA Roadmap identifies nine ‘sections’ in hematology: normal hematopoiesis, malignant lymphoid and myeloid diseases, anemias and related diseases, platelet disorders, blood coagulation and hemostatic disorders, transfusion medicine, infections in hematology, and hematopoietic stem cell transplantation. These sections span 60 smaller groups of diseases or disorders. The EHA Roadmap identifies priorities and needs across the field of hematology, including those to develop targeted therapies based on genomic profiling and chemical biology, to eradicate minimal residual malignant disease, and to develop cellular immunotherapies, combination treatments, gene therapies, hematopoietic stem cell treatments, and treatments that are better tolerated by elderly patients